GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Adolor Corporation (ADLR) [hlAlert]

Rating:
Outperform
ADLR
up 294.21 %

Adolor Corporation (ADLR) rated Outperform with price target $5 by Wedbush

Posted on: Friday,  Oct 22, 2010  1:25 PM ET by Wedbush

Wedbush rated Outperform Adolor Corporation (NASDAQ: ADLR) on 10/22/2010, when the stock price was $1.21. Since
then, Adolor Corporation has gained 294.21% as of 12/09/2011's recent price of $4.77.
If you would have followed this Wedbush 's recommendation on ADLR, you would have gained 294.21% of your investment in 413 days.

Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company?s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Wedbush is Headquartered in Los Angeles, California with over 90 offices and more than 125 correspondent offices, our commitment to providing relentless, customized service is the foundation of our consistent growth. We deliver superior investment ideas and products through exceptional customer care, financial security, continuity and advanced technology.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/22/2010 1:25 PM Buy
None
1.21 5.00
as of 12/31/2010
1 Week up  16.94 %
1 Month up  10.40 %
3 Months up  14.04 %
1 YTD up  14.04 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy